Tenaya Therapeutics

NSQ:TNYA · US87990A1060

BiotechnologySmall

360

Medium confidence — indicative

Value36

Profit price47

Cash yield1

Owner Earnings Yield1

Dividend Yield1

Sales & asset price34

Price/Sales65

EV / Gross Profit1

Price/Book35

Quality43

Returns on capital41

Return on Capital41

Cash Return on Capital46

Return on Equity36

Profit margins40

Cash backing40

Accruals78

Owner Earnings Margin1

Growth—

Sales growth—

Profit growth79

Reinvestment4

Price momentum22

Safety50

Debt load52

Debt serviceability50

Refinancing99

Debt Payback1

Liquidity75

Sentiment49

Analyst ratings51

Expectations trend50

Market mood45

Value Creation8/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Tenaya Therapeutics clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 4/5 components.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2016

Employees86

Websitetenayatherapeutics.com

ISINUS87990A1060

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

InflammationCardiovascularGeneticsBiotechnologyHealth CareTherapeutics

Description

Tenaya Therapeutics, Inc. operates as a clinical-stage biotechnology company that focuses on discovering, developing and delivering curative therapies that address the underlying drivers of heart disease. The company primarily focuses on advancing i…

Analysis

Middle-of-the-road

Tenaya Therapeutics, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is mixed and the balance sheet is adequate. The company scores 8/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Tenaya Therapeutics with its peers

Taysha Gene Therapies

NSQ:TSHA

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Rocket Pharmaceuticals

NMQ:RCKT

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Lexeo Therapeutics

NMQ:LXEO

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Regenxbio

NSQ:RGNX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Tango Therapeutics

NMQ:TNGX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Stoke Therapeutics

NSQ:STOK

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →